Mirna Reports First Quarter 2017 Financial Results

AUSTIN, Texas--(BUSINESS WIRE)--Mirna Therapeutics, Inc. (Nasdaq:MIRN), a biopharmaceutical company, today reported financial results for the first quarter of 2017 and provided a corporate update.

Following its late 2016 discontinuation of all research and development activities, the Company engaged a financial advisor and has been pursuing activities to evaluate strategic alternatives, including a possible merger or sale of the Company. Further operating cost and workforce reductions were also implemented to reduce overall cash burn.

We are committed to serving our shareholders’ best interests and are continuing our strategic discussions with third parties in an effort to consummate a transaction,” said President and CEO Paul Lammers, M.D., M.Sc.

Back to news